Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.48 |
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31462770 | 0.91 | PDK4 (0.48) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL24678243 | 0.89 | PDK4 (0.46) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL2079005 | 0.88 | PDK4 (0.53) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL24678007 | 0.88 | PDK4 (0.46) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL18589100 | 0.87 | PDK4 (0.48) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL17054327 | 0.85 | GRM1 (0.49) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL18589249 | 0.84 | PDK4 (0.46) | PDK4GRM1GRM5NAMPTALDH1A1 | |
| SCHEMBL12883596 | 0.84 | PDK4 (0.53) | PDK4GRM1GRM5NAMPTCDK9 | |
| SCHEMBL12883597 | 0.84 | PDK4 (0.53) | PDK4GRM1GRM5NAMPTCDK9 | |
| SCHEMBL3435563 | 0.83 | GRM1 (0.47) | PDK4GRM1GRM5NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4083038-A1 | PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | PDK4 1001/4885GRM1 1918/4885GRM5 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.